Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Recruiting 2Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 5Plasma cell 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 307Pancreatic Neoplasms 207Stomach Neoplasms 161Carcinoma, Hepatocellular 160Colonic Neoplasms 115Rectal Neoplasms 104Esophageal Neoplasms 92Carcinoma, Non-Small-Cell Lung 91Breast Neoplasms 76Neoplasms 67Liver Neoplasms 62Ovarian Neoplasms 60Melanoma 51Neoplasm Metastasis 50Cholangiocarcinoma 49Lung Neoplasms 48Squamous Cell Carcinoma of Head and Neck 37Esophageal Squamous Cell Carcinoma 37Gastrointestinal Neoplasms 36Carcinoma, Renal Cell 35Prostatic Neoplasms 33Uterine Cervical Neoplasms 32Sarcoma 32Endometrial Neoplasms 32Biliary Tract Neoplasms 31Anus Neoplasms 30Head and Neck Neoplasms 27Urinary Bladder Neoplasms 22Triple Negative Breast Neoplasms 21Adenocarcinoma Of Esophagus 21

Interventions

cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma, Alveolar Soft Part × Gastrointestinal × Clear all
NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡